(1)A pharmacist or pharmacist intern who dispenses a self-administered hormonal contraceptive under Section 26B-4-504:
(1)(a) shall obtain a completed self-screening risk assessment questionnaire, that has been approved by the division in collaboration with the Board of Pharmacy and the Medical Licensing Board, from the patient before dispensing the self-administered hormonal contraceptive;
(1)(b) if the results of the evaluation in Subsection (1)(a) indicate that it is unsafe to dispense a self-administered hormonal contraceptive to a patient:
(1)(b)(i) may not dispense a self-administered hormonal contraceptive to the patient; and
(1)(b)(ii) shall refer the patient to a primary care or women's health care practitioner;
(1)(c) may not continue to dispense a self-administered hormonal con
Free access — add to your briefcase to read the full text and ask questions with AI
(1) A pharmacist or pharmacist intern who dispenses a self-administered hormonal contraceptive under Section 26B-4-504:
(1)(a) shall obtain a completed self-screening risk assessment questionnaire, that has been approved by the division in collaboration with the Board of Pharmacy and the Medical Licensing Board, from the patient before dispensing the self-administered hormonal contraceptive;
(1)(b) if the results of the evaluation in Subsection (1)(a) indicate that it is unsafe to dispense a self-administered hormonal contraceptive to a patient:
(1)(b)(i) may not dispense a self-administered hormonal contraceptive to the patient; and
(1)(b)(ii) shall refer the patient to a primary care or women's health care practitioner;
(1)(c) may not continue to dispense a self-administered hormonal contraceptive to a patient for more than 24 months after the date of the initial prescription without evidence that the patient has consulted with a primary care or women's health care practitioner during the preceding 24 months; and
(1)(d) shall provide the patient with:
(1)(d)(i) written information regarding:
(1)(d)(i)(A) the importance of seeing the patient's primary care practitioner or women's health care practitioner to obtain recommended tests and screening; and
(1)(d)(i)(B) the effectiveness and availability of long-acting reversible contraceptives as an alternative to self-administered hormonal contraceptives; and
(1)(d)(ii) a copy of the record of the encounter with the patient that includes:
(1)(d)(ii)(A) the patient's completed self-assessment tool; and
(1)(d)(ii)(B) a description of the contraceptives dispensed, or the basis for not dispensing a contraceptive.
(2) If a pharmacist dispenses a self-administered hormonal contraceptive to a patient, the pharmacist shall, at a minimum, provide patient counseling to the patient regarding:
(2)(a) the appropriate administration and storage of the self-administered hormonal contraceptive;
(2)(b) potential side effects and risks of the self-administered hormonal contraceptive;
(2)(c) the need for backup contraception;
(2)(d) when to seek emergency medical attention; and
(2)(e) the risk of contracting a sexually transmitted infection or disease, and ways to reduce the risk of contraction.
(3) The division, in collaboration with the Board of Pharmacy and the Medical Licensing Board, shall make rules in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, establishing the self-screening risk assessment questionnaire described in Subsection (1)(a).